One such anti–PD–1 antibody drug, nivolumab, produced complete or partial responses in non–small–cell lung cancer (NSCLC), melanoma, and renal–cell cancer in clinical trials and was approved to treat metastatic melanoma in July 2014 in Japan and in December 2014 by the US FDA [15,16]. Here, PDCD1 is linked to melanoma.